The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy
Open accessAbstract
BACKGROUND The effect of CYP2C19 genotype on treatment outcomes with ticagrelor or prasugrel as compared to clopidogrel is unclear. METHODS Databases through February 19th, 2020 were searched for studies reporting the effect of CYP2C19 genotype on ischemic outcomes during ticagrelor or prasugrel versus clopidogrel treatment. Study eligibility required outcomes reported for CYP2C19 genotype status and clopidogrel and alternate P2Y12 inhibitors in coronary artery disease (CAD) patients with at least 50% undergoing percutaneous coronary intervention (PCI). The primary analysis consisted of randomized controlled trials (RCTs). A secondary analysis was conducted by adding non-RCTs to the primary analysis. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia. Meta-analysis compared the two drug regimens and tested interaction with CYP2C19 genotype. RESULTS Of 1,335 studies identified, 7 RCTs were included (15,949 patients, mean age 62 years, 77% had PCI, 98% had acute coronary syndromes). Statistical heterogeneity was minimal and risk of bias was low. Ticagrelor and prasugrel as compared to clopidogrel resulted in a significant reduction in ischemic events (relative risk (RR) 0.70; 95%CI 0.59–0.83) in CYP2C19 loss-of-function carriers but not in non-carriers (RR 1.0; 95%CI 0.80–1.25). The test of interaction based on CYP2C19 genotype status was statistically significant (p=0.013) suggesting that CYP2C19 genotype modified the effect. An additional 4 observational studies were found and adding them to the analysis provided the same conclusions (p value of the test of interaction=<0.001). CONCLUSIONS The effect of ticagrelor or prasugrel compared to clopidogrel in reducing ischemic events in patients with CAD who predominantly undergo PCI is primarily based on the presence of CYP2C19 loss-of-function carrier status. These results support genetic testing prior to prescribing P2Y12 inhibitor therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Cardiovascular pharmacogenomics and individualized drug therapy
Pereira, N. L., & Weinshilboum, R. M. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.154 · Cited by 72
Self-citation
Cited by
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., Kisor, D. F., Limdi, N. A., Lee, Y. M., Scott, S. A., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2526 · Cited by 519
Clinical utility of polygenic risk scores for coronary artery disease
Klarin, D., & Natarajan, P. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00638-w · Cited by 152
Metadata
- Authors
- Pereira, N. L., Rihal, C., Lennon, R., Marcus, G., Shrivastava, S., Bell, M. R., So, D., Geller, N., Goodman, S. G., Hasan, A., Lerman, A., Rosenberg, Y., Bailey, K., Murad, M. H., & Farkouh, M. E.
- Venue
- JACC: Cardiovascular Interventions
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 14
- Issue
- 7
- Pages
- 739-750
- ISSN
- 1876-7605 (ISSN-L)
- 1936-8798
- OpenAlex
- W3136631970
- Cited by
- 166
- References
- 4
- FWCI
- 20.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy. https://app.cochat.ai/papers/10.1016/j.jcin.2021.01.024
- The paper
- Pereira, N. L., Rihal, C., Lennon, R., Marcus, G., Shrivastava, S., Bell, M. R., So, D., Geller, N., Goodman, S. G., Hasan, A., Lerman, A., Rosenberg, Y., Bailey, K., Murad, M. H., & Farkouh, M. E. (2021). Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2021.01.024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.